{"id":7119,"date":"2021-06-02T18:48:36","date_gmt":"2021-06-02T18:48:36","guid":{"rendered":"http:\/\/cvx.vc\/?p=7119"},"modified":"2021-06-02T18:48:36","modified_gmt":"2021-06-02T18:48:36","slug":"dansk-biotech-virksomhed-gor-klar-til-naeste-kapitalrejsning","status":"publish","type":"post","link":"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-virksomhed-gor-klar-til-naeste-kapitalrejsning\/","title":{"rendered":"Dansk biotech-virksomhed g\u00f8r klar til n\u00e6ste kapitalrejsning"},"content":{"rendered":"<p><i><span style=\"font-weight: 400;\">Billede: PR-foto NMD Pharma<\/span><\/i><\/p>\n<p><span style=\"font-weight: 400;\">Den danske medicinalvirksomhed netop startet et nyt observationsstudie sammen med kliniske samarbejdspartnere i USA. Samarbejdspartnerne er bl.a. selskabets mange\u00e5rige samarbejdspartner, professor William David Arnold.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Ved at bruge en r\u00e6kke etablerede neurofysiologiske biomark\u00f8rer skal NMD i studiet unders\u00f8ge, om patienter med aldersrelateret muskelsv\u00e6kkelse, sarkopeni, udviser tegn p\u00e5 neuromuskul\u00e6r dysfunktion.<\/span><\/p>\n<p><i><span style=\"font-weight: 400;\">&#8220;Den prim\u00e6re mekanisme, som vi arbejder med i NMD Pharma, er h\u00e6mning af ClC-1-ionkanalen. Denne ionkanal findes kun i skeletmuskler, og kan derfor have potentiale i flere forskellige neuromuskul\u00e6re sygdomme,&#8221;<\/span><\/i><span style=\"font-weight: 400;\"> siger adm. direkt\u00f8r Thomas Holm Pedersen.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Resultaterne fra dette studie samt resultater fra lignende studier, kan f\u00e5 markant indflydelse p\u00e5 den n\u00e6ste kapitalrejsning, som selskabet s\u00e5 sm\u00e5t er g\u00e5et i gang med at forberede.<\/span><\/p>\n<p><i><span style=\"font-weight: 400;\">&#8220;Det er klart, at flere kliniske studier vil kr\u00e6ve yderligere finansiering, s\u00e5 det er noget, vi lige s\u00e5 stille begynder at kigge p\u00e5 i forhold til at have muligheden for at drive vores programmer videre frem,&#8221;<\/span><\/i><span style=\"font-weight: 400;\"> siger Thomas Holm Pedersen.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">I 2018 rejste NMD Pharma 280 mio. kr. og har for nyligt indkasseret den seneste tranche fra den investeringsrunde. Virksomheden f\u00e5r er derfor fortsat velfinansieret, men vil gerne v\u00e6re ude i god tid.<\/span><\/p>\n<p><i><span style=\"font-weight: 400;\">&#8220;Vi mangler ikke pengene akut inden for den n\u00e6rmeste fremtid, og har ogs\u00e5 opbakning fra et st\u00e6rkt syndikat og har gjort gode fremskridt siden den sidste runde. S\u00e5 vi mener, at vi har gode foruds\u00e6tninger for en kommende kapitalrejsningsrunde,&#8221;<\/span><\/i><span style=\"font-weight: 400;\"> siger Thomas Holm Pedersen.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">L\u00e6s hele historien p\u00e5 KapitalWatch <\/span><a href=\"https:\/\/kapwatch.dk\/seneste\/article13020796.ece?utm_campaign=KapitalWatch&amp;utm_content=2021-06-01&amp;utm_medium=email&amp;utm_source=kapitalwatch\"><b><i>her<\/i><\/b><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>I 2020 startede NMD Pharma kliniske fors\u00f8g. Nu ser de n\u00e6rmere p\u00e5 andre sygdomme, inden selskabet g\u00e5r i gang med at rejse kapital igen.<\/p>\n","protected":false},"author":25,"featured_media":7114,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[18],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.4 (Yoast SEO v23.5) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Dansk biotech-virksomhed g\u00f8r klar til n\u00e6ste kapitalrejsning | CVX Ventures<\/title>\n<meta name=\"description\" content=\"I 2020 startede NMD Pharma kliniske fors\u00f8g. Nu ser de n\u00e6rmere p\u00e5 andre sygdomme, inden selskabet g\u00e5r i gang med at rejse kapital igen.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-virksomhed-gor-klar-til-naeste-kapitalrejsning\/\" \/>\n<meta property=\"og:locale\" content=\"da_DK\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dansk biotech-virksomhed g\u00f8r klar til n\u00e6ste kapitalrejsning\" \/>\n<meta property=\"og:description\" content=\"I 2020 startede NMD Pharma kliniske fors\u00f8g. Nu ser de n\u00e6rmere p\u00e5 andre sygdomme, inden selskabet g\u00e5r i gang med at rejse kapital igen.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-virksomhed-gor-klar-til-naeste-kapitalrejsning\/\" \/>\n<meta property=\"og:site_name\" content=\"CVX Ventures\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/cvxventures\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-02T18:48:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cvx.vc\/wp-content\/uploads\/2021\/06\/NMD-Pharma.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"960\" \/>\n\t<meta property=\"og:image:height\" content=\"540\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Kim Jessica Axholt\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Skrevet af\" \/>\n\t<meta name=\"twitter:data1\" content=\"Kim Jessica Axholt\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimeret l\u00e6setid\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-virksomhed-gor-klar-til-naeste-kapitalrejsning\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-virksomhed-gor-klar-til-naeste-kapitalrejsning\/\"},\"author\":{\"name\":\"Kim Jessica Axholt\",\"@id\":\"https:\/\/cvx.vc\/da\/#\/schema\/person\/4cbb55244c8f14962adcd709672339bb\"},\"headline\":\"Dansk biotech-virksomhed g\u00f8r klar til n\u00e6ste kapitalrejsning\",\"datePublished\":\"2021-06-02T18:48:36+00:00\",\"dateModified\":\"2021-06-02T18:48:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-virksomhed-gor-klar-til-naeste-kapitalrejsning\/\"},\"wordCount\":267,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cvx.vc\/da\/#organization\"},\"image\":{\"@id\":\"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-virksomhed-gor-klar-til-naeste-kapitalrejsning\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cvx.vc\/wp-content\/uploads\/2021\/06\/NMD-Pharma.jpg\",\"articleSection\":[\"Blogindl\u00e6g\"],\"inLanguage\":\"da-DK\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-virksomhed-gor-klar-til-naeste-kapitalrejsning\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-virksomhed-gor-klar-til-naeste-kapitalrejsning\/\",\"url\":\"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-virksomhed-gor-klar-til-naeste-kapitalrejsning\/\",\"name\":\"Dansk biotech-virksomhed g\u00f8r klar til n\u00e6ste kapitalrejsning | CVX Ventures\",\"isPartOf\":{\"@id\":\"https:\/\/cvx.vc\/da\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-virksomhed-gor-klar-til-naeste-kapitalrejsning\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-virksomhed-gor-klar-til-naeste-kapitalrejsning\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cvx.vc\/wp-content\/uploads\/2021\/06\/NMD-Pharma.jpg\",\"datePublished\":\"2021-06-02T18:48:36+00:00\",\"dateModified\":\"2021-06-02T18:48:36+00:00\",\"description\":\"I 2020 startede NMD Pharma kliniske fors\u00f8g. Nu ser de n\u00e6rmere p\u00e5 andre sygdomme, inden selskabet g\u00e5r i gang med at rejse kapital igen.\",\"breadcrumb\":{\"@id\":\"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-virksomhed-gor-klar-til-naeste-kapitalrejsning\/#breadcrumb\"},\"inLanguage\":\"da-DK\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-virksomhed-gor-klar-til-naeste-kapitalrejsning\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"da-DK\",\"@id\":\"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-virksomhed-gor-klar-til-naeste-kapitalrejsning\/#primaryimage\",\"url\":\"https:\/\/cvx.vc\/wp-content\/uploads\/2021\/06\/NMD-Pharma.jpg\",\"contentUrl\":\"https:\/\/cvx.vc\/wp-content\/uploads\/2021\/06\/NMD-Pharma.jpg\",\"width\":960,\"height\":540},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-virksomhed-gor-klar-til-naeste-kapitalrejsning\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hjem\",\"item\":\"https:\/\/cvx.vc\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dansk biotech-virksomhed g\u00f8r klar til n\u00e6ste kapitalrejsning\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cvx.vc\/da\/#website\",\"url\":\"https:\/\/cvx.vc\/da\/\",\"name\":\"CVX Ventures\",\"description\":\"Vi investerer i Danmarks mest lovende v\u00e6kstvirksomheder\",\"publisher\":{\"@id\":\"https:\/\/cvx.vc\/da\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cvx.vc\/da\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"da-DK\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cvx.vc\/da\/#organization\",\"name\":\"CVX Ventures | Danmarks mest v\u00e6rdiskabende investor\",\"url\":\"https:\/\/cvx.vc\/da\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"da-DK\",\"@id\":\"https:\/\/cvx.vc\/da\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cvx.vc\/wp-content\/uploads\/2022\/08\/Group-241.svg\",\"contentUrl\":\"https:\/\/cvx.vc\/wp-content\/uploads\/2022\/08\/Group-241.svg\",\"width\":827,\"height\":394,\"caption\":\"CVX Ventures | Danmarks mest v\u00e6rdiskabende investor\"},\"image\":{\"@id\":\"https:\/\/cvx.vc\/da\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/cvxventures\/\",\"https:\/\/www.linkedin.com\/company\/cvxventures\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cvx.vc\/da\/#\/schema\/person\/4cbb55244c8f14962adcd709672339bb\",\"name\":\"Kim Jessica Axholt\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"da-DK\",\"@id\":\"https:\/\/cvx.vc\/da\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/272190fb9f112ece965f1f17765feb31?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/272190fb9f112ece965f1f17765feb31?s=96&d=mm&r=g\",\"caption\":\"Kim Jessica Axholt\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Dansk biotech-virksomhed g\u00f8r klar til n\u00e6ste kapitalrejsning | CVX Ventures","description":"I 2020 startede NMD Pharma kliniske fors\u00f8g. Nu ser de n\u00e6rmere p\u00e5 andre sygdomme, inden selskabet g\u00e5r i gang med at rejse kapital igen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-virksomhed-gor-klar-til-naeste-kapitalrejsning\/","og_locale":"da_DK","og_type":"article","og_title":"Dansk biotech-virksomhed g\u00f8r klar til n\u00e6ste kapitalrejsning","og_description":"I 2020 startede NMD Pharma kliniske fors\u00f8g. Nu ser de n\u00e6rmere p\u00e5 andre sygdomme, inden selskabet g\u00e5r i gang med at rejse kapital igen.","og_url":"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-virksomhed-gor-klar-til-naeste-kapitalrejsning\/","og_site_name":"CVX Ventures","article_publisher":"https:\/\/www.facebook.com\/cvxventures\/","article_published_time":"2021-06-02T18:48:36+00:00","og_image":[{"width":960,"height":540,"url":"https:\/\/cvx.vc\/wp-content\/uploads\/2021\/06\/NMD-Pharma.jpg","type":"image\/jpeg"}],"author":"Kim Jessica Axholt","twitter_card":"summary_large_image","twitter_misc":{"Skrevet af":"Kim Jessica Axholt","Estimeret l\u00e6setid":"2 minutter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-virksomhed-gor-klar-til-naeste-kapitalrejsning\/#article","isPartOf":{"@id":"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-virksomhed-gor-klar-til-naeste-kapitalrejsning\/"},"author":{"name":"Kim Jessica Axholt","@id":"https:\/\/cvx.vc\/da\/#\/schema\/person\/4cbb55244c8f14962adcd709672339bb"},"headline":"Dansk biotech-virksomhed g\u00f8r klar til n\u00e6ste kapitalrejsning","datePublished":"2021-06-02T18:48:36+00:00","dateModified":"2021-06-02T18:48:36+00:00","mainEntityOfPage":{"@id":"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-virksomhed-gor-klar-til-naeste-kapitalrejsning\/"},"wordCount":267,"commentCount":0,"publisher":{"@id":"https:\/\/cvx.vc\/da\/#organization"},"image":{"@id":"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-virksomhed-gor-klar-til-naeste-kapitalrejsning\/#primaryimage"},"thumbnailUrl":"https:\/\/cvx.vc\/wp-content\/uploads\/2021\/06\/NMD-Pharma.jpg","articleSection":["Blogindl\u00e6g"],"inLanguage":"da-DK","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cvx.vc\/da\/insights\/dansk-biotech-virksomhed-gor-klar-til-naeste-kapitalrejsning\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-virksomhed-gor-klar-til-naeste-kapitalrejsning\/","url":"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-virksomhed-gor-klar-til-naeste-kapitalrejsning\/","name":"Dansk biotech-virksomhed g\u00f8r klar til n\u00e6ste kapitalrejsning | CVX Ventures","isPartOf":{"@id":"https:\/\/cvx.vc\/da\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-virksomhed-gor-klar-til-naeste-kapitalrejsning\/#primaryimage"},"image":{"@id":"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-virksomhed-gor-klar-til-naeste-kapitalrejsning\/#primaryimage"},"thumbnailUrl":"https:\/\/cvx.vc\/wp-content\/uploads\/2021\/06\/NMD-Pharma.jpg","datePublished":"2021-06-02T18:48:36+00:00","dateModified":"2021-06-02T18:48:36+00:00","description":"I 2020 startede NMD Pharma kliniske fors\u00f8g. Nu ser de n\u00e6rmere p\u00e5 andre sygdomme, inden selskabet g\u00e5r i gang med at rejse kapital igen.","breadcrumb":{"@id":"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-virksomhed-gor-klar-til-naeste-kapitalrejsning\/#breadcrumb"},"inLanguage":"da-DK","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cvx.vc\/da\/insights\/dansk-biotech-virksomhed-gor-klar-til-naeste-kapitalrejsning\/"]}]},{"@type":"ImageObject","inLanguage":"da-DK","@id":"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-virksomhed-gor-klar-til-naeste-kapitalrejsning\/#primaryimage","url":"https:\/\/cvx.vc\/wp-content\/uploads\/2021\/06\/NMD-Pharma.jpg","contentUrl":"https:\/\/cvx.vc\/wp-content\/uploads\/2021\/06\/NMD-Pharma.jpg","width":960,"height":540},{"@type":"BreadcrumbList","@id":"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-virksomhed-gor-klar-til-naeste-kapitalrejsning\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hjem","item":"https:\/\/cvx.vc\/"},{"@type":"ListItem","position":2,"name":"Dansk biotech-virksomhed g\u00f8r klar til n\u00e6ste kapitalrejsning"}]},{"@type":"WebSite","@id":"https:\/\/cvx.vc\/da\/#website","url":"https:\/\/cvx.vc\/da\/","name":"CVX Ventures","description":"Vi investerer i Danmarks mest lovende v\u00e6kstvirksomheder","publisher":{"@id":"https:\/\/cvx.vc\/da\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cvx.vc\/da\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"da-DK"},{"@type":"Organization","@id":"https:\/\/cvx.vc\/da\/#organization","name":"CVX Ventures | Danmarks mest v\u00e6rdiskabende investor","url":"https:\/\/cvx.vc\/da\/","logo":{"@type":"ImageObject","inLanguage":"da-DK","@id":"https:\/\/cvx.vc\/da\/#\/schema\/logo\/image\/","url":"https:\/\/cvx.vc\/wp-content\/uploads\/2022\/08\/Group-241.svg","contentUrl":"https:\/\/cvx.vc\/wp-content\/uploads\/2022\/08\/Group-241.svg","width":827,"height":394,"caption":"CVX Ventures | Danmarks mest v\u00e6rdiskabende investor"},"image":{"@id":"https:\/\/cvx.vc\/da\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/cvxventures\/","https:\/\/www.linkedin.com\/company\/cvxventures\/"]},{"@type":"Person","@id":"https:\/\/cvx.vc\/da\/#\/schema\/person\/4cbb55244c8f14962adcd709672339bb","name":"Kim Jessica Axholt","image":{"@type":"ImageObject","inLanguage":"da-DK","@id":"https:\/\/cvx.vc\/da\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/272190fb9f112ece965f1f17765feb31?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/272190fb9f112ece965f1f17765feb31?s=96&d=mm&r=g","caption":"Kim Jessica Axholt"}}]}},"_links":{"self":[{"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/posts\/7119"}],"collection":[{"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/users\/25"}],"replies":[{"embeddable":true,"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/comments?post=7119"}],"version-history":[{"count":0,"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/posts\/7119\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/media\/7114"}],"wp:attachment":[{"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/media?parent=7119"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/categories?post=7119"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/tags?post=7119"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}